@2024 Afarand., IRAN
ISSN: 2251-8215 Sarem Journal of Reproductive Medicine 2017;1(3):89-95
ISSN: 2251-8215 Sarem Journal of Reproductive Medicine 2017;1(3):89-95
Abberant Lymphocytes Rate after Gamma-Irradiationn as a Biomarker of Breast Cancer
ARTICLE INFO
Article Type
Original ResearchAuthors
Mojtahedi F. (1)Pooladi A. (2)
Sirati F. (3)
Kaihani E. (1)
Akhlaghpour Sh. (4)
Karimlou M. (5)
Bagherizadeh I. (6)
Fallah M. (1)
Ghasemi Firouzabadi S. (1)
Behjati F. (*)
(*) Genetic Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran
(1) Genetic Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran
(2) “Sarem Fertility & Infertility Research Center (SAFIR)” and “Sarem Cell Research Center (SCRC)”, Sarem Women’s Hospital, Tehran, Iran
(3) Surgery Department, Medicine Faculty, Tehran University of Medical Sciences, Tehran, Iran
(4) Navid Medical Center, Tehran, Iran
(5) Statistics Department, Medicine Faculty, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran
(6) “Sarem Cell Research Center (SCRC)” and “Medical Genetics Department”, Tehran, Iran
Correspondence
Article History
Received: May 15, 2016Accepted: June 25, 2016
ePublished: August 15, 2017
BRIEF TEXT
Breast cancer is the most common malignancy in women [1]. ... [2-4].In developing countries, the incidence of breast cancer is also increasing [5].
.. [6]. Laboratory tests are one of the most important and most effective early diagnostic tools that are based on the evaluation of markers in available body fluids such as peripheral blood. One of the indicated markers is the radiation sensitivity of the lymphocyte. Chromosomes tend to be sensitive to radiation in most cancers, such as breast cancer, a percentage of colorectal cancer, or cancers of the head and neck. About 5 to 14% of the natural population is also allergic to radiation. Therefore, it has been suggested that chromosomal sensitivity to radiation be used as an indicator of the potential for cancer. Differences in the ability to repair DNA may cause a change in radiation sensitivity among normal individuals [5].
The aim of this study was to evaluate the sensitivity of radiation in non-inherited breast cancer in Iranian women.
This study is an observational-analytical study carried out using a case-control method.
Individuals with non-inherited breast cancer were examined at Mehrad Hospital in Tehran compared with healthy people.
A total of 32 individuals with non-inherited breast cancer were studied. These patients did not receive any treatment at the start of the study. Thirty healthy subjects were selected as control group, who had no history of cancer in their first and second degree relatives. Since access to healthy volunteers who had all criteria for entering the study, along with the criteria for matching on the basis of the variables, were limited, in some variables, such as age at the first pregnancy, menarche age and age of menopause, the two groups were identical and in Others, such as the age and the number of pregnancies, this consistency was not achieved that with the help of statistical evaluations, the effect of these variables was checked so that, if there was an effect on the outcome, it could be counterbalanced.
Before sampling, consent was taken from all the participants. 5 cc of Heparin blood was taken from all the participants. Samples were left at 4 ° C for 24 hours and then cultured. In the patient group, all clinical parameters such as tumor size, lymph node involvement status, estrogen receptor and progesterone receptor status, status of expression of p53, HER-2 and grade stage genes were studied and recorded through patient files. The RPMI 1640 culture media which contained bicarbonate sodium and L-glutamine (Eurocolone Lot No: ECM 0495D), penicillin-streptomycin (Eurocolone Cat No: ECB3001D), Eurocolone Lot No: ECS0170D and phytohemagglutinin (GIBCO Cat No: 10576- 015) were used. According to the chromosomal decomposition program using G2, irradiation was performed 72 hours after cell culture. The incident beam was gamma ray with a dose of 0.4 Gy. Removal of cells: Half an hour after radiation by adding calcium, the cells stopped in the metaphase step [7-15]. The second step was to adjoin them with a hypothalamic solution (Hypotone). Due to this proximity, the cells were bulky and the chromosomes got enough space to disperse within the lymphocytes. The third stage is the stabilization of the cells. Finally, samples were prepared and examined after staining. From each sample, three cultures were prepared, two of which were exposed to radiation, and third culture as control culture in all conditions was similar to the other two cultures except irradiation. From the irradiation cultures, a total of 50 cells were examined and from control culture, also, 50 cells were removed for chromosomal counts and evaluation. In the microscopic analysis of metaphyseal lymphocytes, the percentage of abnormal cells was used to determine the sensitivity of the radiation. Maladaptive cells are counted based on the existence of failures that cause abnormalities, chromatid and chromosome clefts (when lack of continuity in the chromatid building is wider than the width of a chromatid), rearrangements (such as chromosomes ring and dicentric chromosome) and the radial forms (3 radial and four radial forms) cells. When discontinuity in the structure of the chromatid is less than one chromatid, chromatid and chromosomal clefts are not considered as chromosomal abnormality. Data were analyzed by SPSS 19 software. Parametric tests (T-test and Paired t-test) and nonparametric tests (Chi-square and Fisher exact tests) were used to assess the significant difference between mean sizes of variables. The evaluation of the radiation sensitivity test was performed based on the characteristics of the system function or the ROC Curves 1 and performing the C-statistics. In this study, in addition to calculate the borderline for each test index based on the Youden index, the sensitivity and specificity of the test were determined at the critical point and the odds ratio was estimated at 95% confidence interval.
The mean age in the affected population was 53.25 years with a range of 32-84 years and in healthy subjects it was 31.33 years with a range of 18-49 years (Table 1). Considering the significant difference in the age and number of pregnancy variables between the two groups of patients and control, it is likely that these two variables can be considered as confounding ones and this can cause the results to be skeptical, that in this respect, the necessary studies were done. Since for a variable to be confounding, the existence of a relationship with both the independent variable and the dependent variable or the same outcome is certain, it should be said that the two variables of age and the number of pregnancies, at least with the condition of exposure to radiation sensitivity, had no definable and definite association. However, statistical analysis took place in this regard. Pearson and Spearman correlation test showed a lack of correlation with the results of the tests and, therefore, there was no ambiguity in term of their likelihood of confusion. The distribution of breast cancer patients according to the tumor stage (according to the three-letter TNM system) showed that 7 patients (23.3%) had stage I, 4 cases (13.3%), had stage Iia; 16 cases (53.3% %) had Stage IIb, one case (3.3%) had stage IIIa and two cases (6.7%) also had stage IIIb. In 62.5%, the tumor had a moderate distinction or a score of 2. In 33.3% of the cases, the tumor had a high distinction or score of 1, and only in 3.1 % of the patients, tumor had a score of 3. The presence or absence of estrogen, progesterone, p53 and HER-2 receptor was a very important part of the study (Table 2). The percentage of abnormal cells in both patient and control groups was significantly different in each case before and after irradiation (Chart. 1, p = 0.00001). Comparing this index between patient groups and the control group, the presence of abnormal cells prior to irradiation showed no significant difference (p> 0.05), but after irradiation, and also the difference in pre and post changes in the percentage of abnormal cells, the difference was significant (p<0.05). Statistical analysis and calculation of C index for percentage of abnormal cells in G2 stage to γ radiation showed that this index can be a significant index with acceptable level of AUC (0.725) (p <0.05) that can be helpful in terms of clinical and decision-making with the odd ratio (Chart 2). The odds ratio at critical point of 61% was 3.818 (CI95% = 1.323-10.942), so that in those who had an increase in the percentage of abnormal cells after irradiation than before irradiation it was equal to or greater than 61%. The probability of being affected was more than 4 times (3.818) more than other people. At the critical point of 61%, the sensitivity of this index was 65.6% and the specificity was 66.6%, which could be acceptable for a test. This test can accurately identify approximately 65.6% of the patients and 66.6% of normal people can be identified as healthy with test. Irradiation caused various clefts and abnormalities in chromosomes (Figures 1 and 2).
... [16-19].In various studies, the sensitivity of radiation in patients with breast cancer has been investigated [14, 15, 20-22]. In some studies, it has shown that about 40% of breast cancer patients have high sensitivity to radiation [8, 12, 13, 23-26]. The sensitivity of the patients to radiation in this study was in line with expectations and in line with other studies. Recently, several studies have tried to address the issue of chromosomal sensitivity at the cytogenetic molecular level and the correlation of the outcome (breast cancer disease) with various characteristics such as genetic variations and even polymorphisms [27-29]. ... [30, 31]. Research results based on new technology in Ukraine are consistent with our research findings regarding the feasibility and applicability of radiation sensitivity testing in the G2 phase of the cell cycle (with X-ray radiation, however) [32]. ... [33-35].
The use of the chromosomally sensitive radiation test can be more accurately assessed in cohort studies in the future.
Iranian women with non-inherited breast cancer have more susceptibility to gamma radiation than healthy women, and show this sensitivity as chromosomal breaks and clefts. Therefore, chromosomally sensitive radiation test, have the usability as an early detection of breast cancer biomarker, or a possible indicator of the potentiality of being affected with this disease.
The Genetics Research Center of the University of Rehabilitation Sciences and Welfare is appreciated for financial support. The staff of the Mehrad Hospital are appreciated for their sincere help in taking samples from the patients in optimal condition. Staff members of the Radiation Therapy Center, are thanked and appreciated who helped us to irradiate the samples, and all those who collaborated with us in this project are appreciated as well.
This research was funded by the Genetics Research Center of the University of and Rehabilitation Sciences and Welfare.
TABLES and CHARTS
Show attach fileCITIATION LINKS
[1]Dumitrescu RG, Cotarla I. Understanding breast cancer risk -Where do we stand in 2005?. J Cell Mol Med. 2005;9(1):208-21.
[2]Miller A. Causes of breast cancer and high-risk groups. In: Harris JR. Breast Diseases. 2th ed. Philadelphia: JB Lippincott; 1991. p. 119.
[3]Santora LM, Mahoney MC, Lawvere S, Englert JJ, Symons AB, Mirand AL. Breast cancer screening beliefs by practice location. BMC Public Health. 2003; 3: 9.
[4]Taylor AMR. Chromosome instability syndromes. Clin haematol. 2001;14(3):631-44.
[5]Haskell CM. Cancer Treatment. 5th ed. Saunders WB, editor. Philadelphia: W.B. Saunders; 2001.
[6]Kahan E, Ibrahim AS, Najjar KE, Ron E, Al-Agha H, Polliack A, et al. Cancer Patterns in the Middle East Special Report from the Middle East Cancer Society. Acta Oncol. 1997;36(6):631-6.
[7]Pichierri P, Franchitto A, Palitti F. Predisposition to cancer and radiosensitivity. Genet Mol Biol. 2000;23(4):1101-5.
[8]Smart V, Curwen GB, Whitehouse CA, Edwards A, Tawn EJ. Chromosomal radiosensitivity: A study of the chromosomal G(2) assay in human blood lymphocytes indicating significant inter-individual variability. Mutat Res. 2003;528(1-2):105-10.
[9]Bryant PE, Gray L, Riches AC, Steel CM, Finnon P, Howe O, et al. The G2 chromosomal radiosensitivity assay. Int J Radiat Biol. 2002;78(9):863-6.
[10]Docherty Z, Georgiou A, Langman C, Kesterton I, Rose S, Camplejohn R, et al. Is chromosome radiosensitivity and apoptotic response to irradiation correlated with cancer susceptibility?. Int J Radiat Biol. 2007;83(1):1-12.
[11]Barwell J, Pangon L, Georgiou A, Kesterton I, Langman C, Arden- Jones A, et al. Lymphocyte radiosensitivity in BRCA1 and BRCA2 mutation carriers and implications for breast cancer susceptibility. Int J Cancer. 2007;121(7):1631-6.
[12]Baeyens A, Thierens H, Claes K, Poppe B, Messiaen L, De Ridder L, et al. Chromosomal radiosensitivity in breast cancer patients with a known or putative genetic predisposition. Br J Cancer. 2002;87(12):1379-85.
[13]Scott D, Barber JB, Spreadborough AR, Burrill W, Roberts SA. Increased chromosomal radiosensitivity in breast cancer patients: A comparison of two assays. Int J Radiat Biol. 1999;75(1):1-10.
[14]Barber JB, Burrill W, Spreadborough AR, Levine E, Warrenb C, Kiltie AE, et al. Relationship between in vitro chromosomal radiosensitivity of peripheral blood lymphocytes and the expression of normal tissue damage following radiotherapy for breast cancer. Radiother Oncol. 2000;55(2):179-86.
[15]Roberts SA, Spreadborough AR, Bulman B, Barber JB, Evans DG, Scott D. Heritability of cellular radiosensitivity: A marker of low penetrance predisposition genes in breast cancer?. Am J Hum Genet. 1999;65(3):784-94.
[16]Boostma D, Kraemer KH, Cleaver JE, Hoeijmakers JHJ. Nucleotide Excision Repair Syndromes: Xeroderma Pigmentosum, Cockayne Syndrome, and Trichothiodystrophy. In: The Metabolic and Molecular Bases of Inherited Disease. 6th ed. New York: McGraw-Hill; 1989.
[17]Cleaver JE. Xeroderma pigmentosum: A human disease in which an initial stage of DNA repair is defective. Proc Natl Acad Sci U S A. 1969;63(2):428-35.
[18]Rary JM, Bender MA, Kelly TE. Cytogenetic status of ataxia telangiectasia. Am J Hum Genet. 1974;26:70
[19]Sanford KK, Parshad R, Price FM, Jones GM, Tarone RE, Eierman L, et al. Enhanced chromatid damage in blood lymphocytes after G2 phase x irradiation, a marker of the ataxia-telangiectasia gene. J Natl Cancer Inst. 1990;82(12):1050-4.
[20]Scott D, Barber JB, Levine EL, Burrill W, Roberts SA. Radiation-induced micronucleus induction in lymphocytes identifies a high frequency of radiosensitive cases among breast cancer patients: A test for predisposition?. Br J Cancer. 1998;77(4):614-20.
[21]Rigaud O, Guedeney G, Duranton I, Leroy A, Doloy MT, Magdelenat H. Genotoxic effects of radiotherapy and chemotherapy on the circulating lymphocytes of breast cancer patients. II. Alteration of DNA repair and chromosome radiosensitivity. Mutat Res. 1990;242(1):25-35.
[22]Samouhos E. Chromosomes, cancer and radiosensitivity. Am J Clin Oncol. 1983;6(4):503-6.
[23]Riches AC, Bryant PE, Steel CM, Gleig A, Robertson AJ, Preece PE, et al. Chromosomal radiosensitivity in G2- phase lymphocytes identifies breast cancer patients with distinctive tumour characteristics. Br J Cancer. 2001;85(8):1157–61.
[24]Terzoudi GI, Jung T, Hain J, Vrouvas J, Margaritis K, Donta-Bakoyianni C, et al. Increased G2 chromosomal radiosensitivity in cancer patients: The role of cdk1/cyclin-B activity level in the mechanisms involved. Int J Radiat Biol. 2000;76(5):607-15.
[25]Parshad R, Price FM, Bohr VA, Cowans KH, Zujewski JA, Sanford KK. Deficient DNA repair capacity, apredisposing factor in breast cancer. Br J Cancer. 1996;74(1):1–5.
[26]Scott D, Spreadborough A, Levine E, Roberts SA. Genetic predisposition in breast cancer. Lancet. 1994;344(8934):1444.
[27]Abdel-RahmanSZ, El-Zein RA. Evaluating the effects of genetic variants of DNA repair genes using cytogenetic mutagen sensitivity approaches. Biomarkers. 2011;16(5):393-404.
[28]Cadwell KK, Curwen GB, Tawn EJ, Winther JF, Boice JD Jr. G2 checkpoint control and G2 chromosomal radiosensitivity in cancer survivors and their families. Mutagenesis. 2011;26(2):291-4.
[29]Kotsopoulos J, Chen Z, Vallis KA, Poll A, Ainsworth P, Narod SA. DNA repair capacity as a possible biomarker of breast cancer risk in female BRCA1 mutation carriers. Br J Cancer. 2007;96(1):118–25.
[30]Baria K, Warren C, Roberts SA, West CM, Scott D. Chromosomal radiosensitivity as a marker of predisposition to common cancers?. Br J Cancer. 2001;84(7):892–6.
[31]Hill JW, Tansavatdi K, Lockett KL, Allen GO, Takita C, Pollack A, et al. Validation of the cell cycle G(2) delay assay in assessing ionizing radiation sensitivity and breast cancer risk. Cancer Manag Res. 2009;1:39-48.
[32]Ryabchenko NM, Glavin OA, Shtefura V, Anikushko MF. Chromosomal radiosensitivity in Ukrainian breast cancer patients and healthy individuals. Exp Oncol. 2012;34(2):121-4.
[33]Wilson PF, Nagasawa H, Fitzek MM, Little JB, Bedford JS. G2-phase chromosomal radiosensitivity of primary fibroblasts from hereditary retinoblastoma family members and some apparently normal controls. Radiat Res. 2010;173(1):62-70.
[34]Hille A, Hofman-Huther H, Kuhnle E, Wilken B, Rave-Frank M, Schmidberger H, et al. Spontaneous and radiation-induced chromosomal instability and persistence of chromosomeaberrations after radiotherapy in lymphocytes from prostate cancer patients. Radiat Environ Biophys. 2010;49(1):27-37.
[35]De Ruyck K, de Gelder V, Van Eijkeren M, Boterberg T, De Neve W, Vral A, et al. Chromosomal radiosensitivity in head and neck cancer patients: Evidence for genetic predisposition?. Br J Cancer. 2008;98(10):1723-38.
[2]Miller A. Causes of breast cancer and high-risk groups. In: Harris JR. Breast Diseases. 2th ed. Philadelphia: JB Lippincott; 1991. p. 119.
[3]Santora LM, Mahoney MC, Lawvere S, Englert JJ, Symons AB, Mirand AL. Breast cancer screening beliefs by practice location. BMC Public Health. 2003; 3: 9.
[4]Taylor AMR. Chromosome instability syndromes. Clin haematol. 2001;14(3):631-44.
[5]Haskell CM. Cancer Treatment. 5th ed. Saunders WB, editor. Philadelphia: W.B. Saunders; 2001.
[6]Kahan E, Ibrahim AS, Najjar KE, Ron E, Al-Agha H, Polliack A, et al. Cancer Patterns in the Middle East Special Report from the Middle East Cancer Society. Acta Oncol. 1997;36(6):631-6.
[7]Pichierri P, Franchitto A, Palitti F. Predisposition to cancer and radiosensitivity. Genet Mol Biol. 2000;23(4):1101-5.
[8]Smart V, Curwen GB, Whitehouse CA, Edwards A, Tawn EJ. Chromosomal radiosensitivity: A study of the chromosomal G(2) assay in human blood lymphocytes indicating significant inter-individual variability. Mutat Res. 2003;528(1-2):105-10.
[9]Bryant PE, Gray L, Riches AC, Steel CM, Finnon P, Howe O, et al. The G2 chromosomal radiosensitivity assay. Int J Radiat Biol. 2002;78(9):863-6.
[10]Docherty Z, Georgiou A, Langman C, Kesterton I, Rose S, Camplejohn R, et al. Is chromosome radiosensitivity and apoptotic response to irradiation correlated with cancer susceptibility?. Int J Radiat Biol. 2007;83(1):1-12.
[11]Barwell J, Pangon L, Georgiou A, Kesterton I, Langman C, Arden- Jones A, et al. Lymphocyte radiosensitivity in BRCA1 and BRCA2 mutation carriers and implications for breast cancer susceptibility. Int J Cancer. 2007;121(7):1631-6.
[12]Baeyens A, Thierens H, Claes K, Poppe B, Messiaen L, De Ridder L, et al. Chromosomal radiosensitivity in breast cancer patients with a known or putative genetic predisposition. Br J Cancer. 2002;87(12):1379-85.
[13]Scott D, Barber JB, Spreadborough AR, Burrill W, Roberts SA. Increased chromosomal radiosensitivity in breast cancer patients: A comparison of two assays. Int J Radiat Biol. 1999;75(1):1-10.
[14]Barber JB, Burrill W, Spreadborough AR, Levine E, Warrenb C, Kiltie AE, et al. Relationship between in vitro chromosomal radiosensitivity of peripheral blood lymphocytes and the expression of normal tissue damage following radiotherapy for breast cancer. Radiother Oncol. 2000;55(2):179-86.
[15]Roberts SA, Spreadborough AR, Bulman B, Barber JB, Evans DG, Scott D. Heritability of cellular radiosensitivity: A marker of low penetrance predisposition genes in breast cancer?. Am J Hum Genet. 1999;65(3):784-94.
[16]Boostma D, Kraemer KH, Cleaver JE, Hoeijmakers JHJ. Nucleotide Excision Repair Syndromes: Xeroderma Pigmentosum, Cockayne Syndrome, and Trichothiodystrophy. In: The Metabolic and Molecular Bases of Inherited Disease. 6th ed. New York: McGraw-Hill; 1989.
[17]Cleaver JE. Xeroderma pigmentosum: A human disease in which an initial stage of DNA repair is defective. Proc Natl Acad Sci U S A. 1969;63(2):428-35.
[18]Rary JM, Bender MA, Kelly TE. Cytogenetic status of ataxia telangiectasia. Am J Hum Genet. 1974;26:70
[19]Sanford KK, Parshad R, Price FM, Jones GM, Tarone RE, Eierman L, et al. Enhanced chromatid damage in blood lymphocytes after G2 phase x irradiation, a marker of the ataxia-telangiectasia gene. J Natl Cancer Inst. 1990;82(12):1050-4.
[20]Scott D, Barber JB, Levine EL, Burrill W, Roberts SA. Radiation-induced micronucleus induction in lymphocytes identifies a high frequency of radiosensitive cases among breast cancer patients: A test for predisposition?. Br J Cancer. 1998;77(4):614-20.
[21]Rigaud O, Guedeney G, Duranton I, Leroy A, Doloy MT, Magdelenat H. Genotoxic effects of radiotherapy and chemotherapy on the circulating lymphocytes of breast cancer patients. II. Alteration of DNA repair and chromosome radiosensitivity. Mutat Res. 1990;242(1):25-35.
[22]Samouhos E. Chromosomes, cancer and radiosensitivity. Am J Clin Oncol. 1983;6(4):503-6.
[23]Riches AC, Bryant PE, Steel CM, Gleig A, Robertson AJ, Preece PE, et al. Chromosomal radiosensitivity in G2- phase lymphocytes identifies breast cancer patients with distinctive tumour characteristics. Br J Cancer. 2001;85(8):1157–61.
[24]Terzoudi GI, Jung T, Hain J, Vrouvas J, Margaritis K, Donta-Bakoyianni C, et al. Increased G2 chromosomal radiosensitivity in cancer patients: The role of cdk1/cyclin-B activity level in the mechanisms involved. Int J Radiat Biol. 2000;76(5):607-15.
[25]Parshad R, Price FM, Bohr VA, Cowans KH, Zujewski JA, Sanford KK. Deficient DNA repair capacity, apredisposing factor in breast cancer. Br J Cancer. 1996;74(1):1–5.
[26]Scott D, Spreadborough A, Levine E, Roberts SA. Genetic predisposition in breast cancer. Lancet. 1994;344(8934):1444.
[27]Abdel-RahmanSZ, El-Zein RA. Evaluating the effects of genetic variants of DNA repair genes using cytogenetic mutagen sensitivity approaches. Biomarkers. 2011;16(5):393-404.
[28]Cadwell KK, Curwen GB, Tawn EJ, Winther JF, Boice JD Jr. G2 checkpoint control and G2 chromosomal radiosensitivity in cancer survivors and their families. Mutagenesis. 2011;26(2):291-4.
[29]Kotsopoulos J, Chen Z, Vallis KA, Poll A, Ainsworth P, Narod SA. DNA repair capacity as a possible biomarker of breast cancer risk in female BRCA1 mutation carriers. Br J Cancer. 2007;96(1):118–25.
[30]Baria K, Warren C, Roberts SA, West CM, Scott D. Chromosomal radiosensitivity as a marker of predisposition to common cancers?. Br J Cancer. 2001;84(7):892–6.
[31]Hill JW, Tansavatdi K, Lockett KL, Allen GO, Takita C, Pollack A, et al. Validation of the cell cycle G(2) delay assay in assessing ionizing radiation sensitivity and breast cancer risk. Cancer Manag Res. 2009;1:39-48.
[32]Ryabchenko NM, Glavin OA, Shtefura V, Anikushko MF. Chromosomal radiosensitivity in Ukrainian breast cancer patients and healthy individuals. Exp Oncol. 2012;34(2):121-4.
[33]Wilson PF, Nagasawa H, Fitzek MM, Little JB, Bedford JS. G2-phase chromosomal radiosensitivity of primary fibroblasts from hereditary retinoblastoma family members and some apparently normal controls. Radiat Res. 2010;173(1):62-70.
[34]Hille A, Hofman-Huther H, Kuhnle E, Wilken B, Rave-Frank M, Schmidberger H, et al. Spontaneous and radiation-induced chromosomal instability and persistence of chromosomeaberrations after radiotherapy in lymphocytes from prostate cancer patients. Radiat Environ Biophys. 2010;49(1):27-37.
[35]De Ruyck K, de Gelder V, Van Eijkeren M, Boterberg T, De Neve W, Vral A, et al. Chromosomal radiosensitivity in head and neck cancer patients: Evidence for genetic predisposition?. Br J Cancer. 2008;98(10):1723-38.